Literature DB >> 29247513

Clinical efficacy of irrigated catheter application of amiodarone during ablation of persistent atrial fibrillation.

Xingfu Huang1, Yanjia Chen2, Yuli Huang3, Hongxin Zhao4, Yanyu Chen1, Liwei He1, Shenrong Liu1, Vikram Shee1, Dingli Xu1, Jian Peng1.   

Abstract

BACKGROUND: Pharmacological treatment during ablation of persistent atrial fibrillation (AF) is common, but utility of irrigated catheter application of amiodarone during ablation of persistent AF remains unclear. HYPOTHESIS: Irrigated catheter application of amiodarone improves quality of ablation and long-term outcomes.
METHODS: We enrolled 90 persistent AF patients who underwent catheter ablation. Patients were randomized to the amiodarone group (n = 45) or control group (n = 45). All patients underwent stepwise ablation beginning with isolation of the pulmonary veins. Next, we performed ablation of linear lesions and focal triggers until sinus rhythm (SR) was achieved. The primary endpoint was documented atrial arrhythmia during follow-up. The secondary endpoint was cardioversion to SR during ablation.
RESULTS: All pulmonary veins were successfully isolated. Conversion of AF to SR occurred more frequently in the amiodarone group than in the control group (33 vs 23 [73.3% vs 51.1%]; P = 0.03). The amiodarone group had lower procedure, radiofrequency, and fluoroscopy times than the control group (167.4 ± 22.5 min vs 186.7 ± 25.3 min; 78.3 ± 14.2 min vs 90.4 ± 15.5 min; and 6.5 ± 1.9 min vs 8.6 ± 2.4 min, respectively; P < 0.05). More importantly, the atrial arrhythmia recurrence-free survival rates were 80% in the amiodarone group and 60% in the control group during the 14.7 ± 7.5-month follow-up (P = 0.043).
CONCLUSIONS: Irrigated catheter application of amiodarone during ablation for persistent AF resulted in higher cardioversion rates and lower procedure times and significantly reduced rates of atrial arrhythmia recurrence.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Amiodarone; Atrial Arrhythmia; Atrial fibrillation; Catheter Ablation; High-Resolution Mapping

Mesh:

Substances:

Year:  2017        PMID: 29247513      PMCID: PMC6490422          DOI: 10.1002/clc.22835

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  21 in total

Review 1.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Josep Brugada; Douglas L Packer; Riccardo Cappato; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; David E Haines; Michel Haissaguerre; Yoshito Iesaka; Warren Jackman; Pierre Jais; Hans Kottkamp; Karl Heinz Kuck; Bruce D Lindsay; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Andrea Natale; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Jeremy N Ruskin; Richard J Shemin
Journal:  Heart Rhythm       Date:  2007-04-30       Impact factor: 6.343

2.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; José Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  Heart Rhythm       Date:  2012-03-01       Impact factor: 6.343

3.  Amiodarone reduces the amount of ablation during catheter ablation for persistent atrial fibrillation.

Authors:  Yosuke Miwa; Hitoshi Minamiguchi; Anil K Bhandari; David S Cannom; Ivan C Ho
Journal:  Europace       Date:  2014-01-19       Impact factor: 5.214

4.  Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE).

Authors:  Sanghamitra Mohanty; Luigi Di Biase; Prasant Mohanty; Chintan Trivedi; Pasquale Santangeli; Rong Bai; John David Burkhardt; Joseph G Gallinghouse; Rodney Horton; Javier E Sanchez; Patrick M Hranitzky; Jason Zagrodzky; Amin Al-Ahmad; Gemma Pelargonio; Dhanunjay Lakkireddy; Madhu Reddy; Giovanni Forleo; Antonio Rossillo; Sakis Themistoclakis; Richard Hongo; Salzwa Beheiry; Michela Casella; Antonio Dello Russo; Claudio Tondo; Andrea Natale
Journal:  Heart Rhythm       Date:  2014-11-18       Impact factor: 6.343

Review 5.  Revisiting pulmonary vein isolation alone for persistent atrial fibrillation: A systematic review and meta-analysis.

Authors:  Aleksandr Voskoboinik; Jeremy T Moskovitch; Nadav Harel; Prashanthan Sanders; Peter M Kistler; Jonathan M Kalman
Journal:  Heart Rhythm       Date:  2017-05       Impact factor: 6.343

6.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.

Authors:  M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

7.  Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation.

Authors:  William Wang; Yun Qing Mei; Xin Hiu Yuan; Xiao Dong Feng
Journal:  J Thorac Cardiovasc Surg       Date:  2015-06-30       Impact factor: 5.209

8.  Ablation of permanent AF: adjunctive strategies to pulmonary veins isolation: targeting AF NEST in sinus rhythm and CFAE in AF.

Authors:  Mauricio Arruda; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2008-07-15       Impact factor: 1.900

9.  Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study).

Authors:  Jean-François Roux; Erica Zado; David J Callans; Fermin Garcia; David Lin; Francis E Marchlinski; Rupa Bala; Sanjay Dixit; Michael Riley; Andrea M Russo; Mathew D Hutchinson; Joshua Cooper; Ralph Verdino; Vickas Patel; Parijat S Joy; Edward P Gerstenfeld
Journal:  Circulation       Date:  2009-09-08       Impact factor: 29.690

10.  Use of antiarrhythmic drugs during ablation of persistent atrial fibrillation: observations from a large single-centre cohort.

Authors:  Jakob Lüker; Arian Sultan; Susanne Sehner; Boris Hoffmann; Helge Servatius; Stephan Willems; Daniel Steven
Journal:  Heart Vessels       Date:  2015-11-06       Impact factor: 2.037

View more
  1 in total

1.  Clinical efficacy of irrigated catheter application of amiodarone during ablation of persistent atrial fibrillation.

Authors:  Xingfu Huang; Yanjia Chen; Yuli Huang; Hongxin Zhao; Yanyu Chen; Liwei He; Shenrong Liu; Vikram Shee; Dingli Xu; Jian Peng
Journal:  Clin Cardiol       Date:  2017-12-16       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.